Medical device company Saluda Medical Pty Limited said on Monday that it has received USD75m under its equity financing with Boston Scientific Corporation (NYSE:BSX) and Redmile Group LLC.
Saluda Medical intends to use the funds for the final stages of development through commercialisation of its Evoke ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic intractable pain of the trunk and limbs.
Boston Scientific, Redmile and one other financial institution participated in the capital raise.
Piper Jaffray acted as financial advisor to Saluda for the equity financing.
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Tissue Regenix secures CE and UKCA certifications for OrthoPure XT
Terumo Corporation expands stroke portfolio in EMEA with SOFIA Flow 88 catheter launch
Crossject advances ZENEO manufacturing with scalable aseptic filling module ahead of product rollout
ZYLOX Unicorn Vascular Closure Device approved in Indonesia
Mindray unveils BeneVision V Series at Euroanaesthesia 2025, advancing precision monitoring
Unicon Pharma and VRR Life Sciences partner support digital transformation in life sciences
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software